YumanityLogo.jpg
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
December 05, 2022 07:30 ET | Yumanity Therapeutics Inc
Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval ...
YumanityLogo.jpg
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 14, 2022 08:16 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for...
YumanityLogo.jpg
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
November 10, 2022 16:15 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) today announced that the registration statement on Form S-4 (the “Registration...
Yumanity Therapeutic
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
August 29, 2022 06:30 ET | Yumanity Therapeutics Inc
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative,...
Yumanity Therapeutic
Yumanity Therapeutics, 자산 매각 및 Kineta와의 합병 제안과 관련해 Form S-4 증권신고서 제출
August 29, 2022 06:30 ET | Yumanity Therapeutics Inc
보스턴, Aug. 29, 2022 (GLOBE NEWSWIRE) -- 혁신적인 질환 조절 방식의 퇴행성 신경질환 치료제를 개발하는 임상 단계 바이오 제약사인 Yumanity Therapeutics, Inc.는 미국 증권거래위원회(SEC)에 Form S-4 증권신고서를 제출했다고 밝혔다. 증권신고서에는 Janssen Pharmaceutica NV에 자산...
YumanityLogo.jpg
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 04, 2022 16:15 ET | Yumanity Therapeutics Inc
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and...
YumanityLogo.jpg
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
June 06, 2022 06:30 ET | Yumanity Therapeutics Inc
Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in...
YumanityLogo.jpg
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 12, 2022 16:45 ET | Yumanity Therapeutics Inc
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
March 24, 2022 16:15 ET | Yumanity Therapeutics Inc
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
February 17, 2022 08:30 ET | Yumanity Therapeutics Inc
BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...